//fpnotebook.com/
Potassium-Sparing Diuretic
Aka: Potassium-Sparing Diuretic, Amiloride, Midamor, Triamterene, Dyrenium- Indications: Potassium-Sparing Diuretics only (aldosterone independent, Amiloride and Triamterene)
- Indications: Aldosterone Antagonists (Spironolactone, Eplerenone)
- Congestive Heart Failure
- Counter aldosterone adverse effects on myocardial remodeling
- Congestive Heart Failure
- Mechanism
- Weak Diuretics (compared with Loop Diuretics or Thiazide Diuretics)
- Potassium-Sparing Diuretics only
- Aldosterone Antagonists (Spironolactone and Eplerenone)
- Commonly used as adjunctive in Congestive Heart Failure management
- Counter aldosterone adverse effects on myocardial remodeling
- Preparations: Potassium-Sparing Diuretics only (aldosterone independent)
- Amiloride (Midamor)
- Dose: 5 mg orally daily (maximum: 20 mg/day)
- Renal excretion (unchanged in urine)
- Half-life: 6 hours
- Triamterene (Dyrenium)
- Dose: 100 mg orally twice daily (maximum: 300 mg/day)
- Typically used as Combination Medication with Thiazide Diuretic
- Rapidly absorbed, highly metabolized in liver and Kidney and rapidly excreted
- Amiloride (Midamor)
- Preparations: Potassium-Sparing Diuretic and Aldosterone Antagonists
- Precautions
- Monitor Serum Potassium after starting a Potassium-Sparing Diuretic in those at Hyperkalemia risk
- Obtain Serum Potassium at 3 days, 7 days and then monthly for the first 3 months
- Monitor Serum Potassium after starting a Potassium-Sparing Diuretic in those at Hyperkalemia risk
- Adverse Effects: Potassium-Sparing Diuretics (Amiloride and Triamterene)
- Hyperkalemia
- Risk factors
- Renal Insufficiency
- Concurrent use with agents that raise Potassium (e.g. ACE Inhibitors, Potassium supplements)
- Risk factors
- Blue Urine Color
- Specific to Triamterene
- Decreased renal perfusion (if Sodium and water depletion)
- Glucose Intolerance
- Potassium-Sparing Diuretics
- Hyperkalemia
-
Drug Interactions
- Potassium supplements (risk of Hyperkalemia)
- References
- Olson (2020) Clinical Pharmacology, Medmaster, Miami, p. 62-3
- Hamilton (2010) Tarason Pocket Pharmacopeia, p. 100
| Medication Costs | ||
|---|---|---|
| Triamterene-HCTZ (on 6/18/2017 at Walmart.com) | ||
| Triamterene-HCTZ 37.5mg-25mg | #30 tablets for $4.00 | $0.13 each |
| Triamterene-HCTZ 37.5mg-25mg | #90 tablets for $10.00 | $0.11 each |
| Triamterene-HCTZ 75mg-50mg | #30 tablets for $4.00 | $0.13 each |
| Triamterene-HCTZ 75mg-50mg | #90 tablets for $10.00 | $0.11 each |
| amiloride (on 5/17/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
| AMILORIDE HCL 5 MG TABLET | Generic | $0.48 each |
| AMILORIDE HCL-HYDROCHLOROTHIAZIDE 5-50 MG TAB | Generic | $0.38 each |
| triamterene (on 5/17/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
| TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP | Generic | $0.17 each |
| TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG TB | Generic | $0.10 each |
| TRIAMTERENE-HYDROCHLOROTHIAZIDE 50-25 MG CAP | Generic | $1.79 each |
| TRIAMTERENE-HYDROCHLOROTHIAZIDE 75-50 MG TAB | Generic | $0.11 each |
| FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. | ||
Amiloride (C0002502) |
|
|---|---|
| Definition (NCI) | A synthetic pyrazine derivative with antikaliuretic and diuretic properties. Amiloride inhibits sodium channels located in the distal tubules and collecting ducts of the kidney, thereby preventing the absorption of sodium and increasing its excretion along with water, to produce naturesis. In response to the hypernatremic conditions in the kidney, the plasma membrane becomes hyperpolarized and electrochemical forces are reduced, which then prevents the excretion of potassium and hydrogen into the lumen. |
| Definition (CSP) | pyrazine compound inhibiting sodium reabsorbtion through sodium channels in renal epithelial cells; used in conjunction with diuretics to spare potassium loss. |
| Definition (MSH) | A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D000584 |
| SnomedCT | 387503008, 87395005 |
| LNC | LP16024-9, MTHU006775 |
| English | Amiloride, Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, Amiloride [Chemical/Ingredient], aMILoride, AMILORIDE, amiloride, Amipramizide, Amiloride (product), Amiloride (substance) |
| Swedish | Amilorid |
| Czech | amilorid |
| Finnish | Amiloridi |
| Russian | AMILORID, АМИЛОРИД |
| Croatian | AMILORID |
| Polish | Amiloryd |
| Japanese | アミロライド, アミパミジン, アミロラジド, アミロリド |
| Spanish | amilorida (producto), amilorida (sustancia), amilorida, Amilorida |
| French | Amiloride |
| German | Amilorid |
| Italian | Amiloride |
| Portuguese | Amilorida |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Midamor (C0026054) |
|
|---|---|
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D000584 |
| English | midamor, Cahill May Roberts Brand of Amiloride Hydrochloride, Merck Brand of Amiloride Hydrochloride, Merck Sharp & Dohme Brand of Amiloride Hydrochloride, Modamide, Midamor |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Triamterene (C0040869) |
|
|---|---|
| Definition (MSH) | A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. |
| Definition (NCI) | A pteridine derivative with potassium-sparing diuretic property. Triamterene blocks the sodium-potassium exchange pump (Na-K-ATPase) in the luminal membrane of principal cells in the late distal tubule, cortical collecting tubule and collecting duct in the kidney. This reversible inhibition of the electrogenic sodium transport decreases the lumen-negative transepithelial potential difference and thus reduces the driving force for K+ movement into the tubular lumen resulting in the inhibition of sodium reabsorption in exchange for K+ and H+. |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D014223 |
| SnomedCT | 12512008, 387053007 |
| LNC | LP14734-5, MTHU001919 |
| English | Triamterene, 2,4,7-Pteridinetriamine, 6-phenyl-, triamterene, triamterene (medication), TRIAMTERENE, Triamterene [Chemical/Ingredient], 6-Phenyl-2,4,7-triaminopteridine, 6-Phenyl-2,4,7-pteridinetriamine, Triamterene (product), Triamterene (substance) |
| Swedish | Triamteren |
| Czech | triamteren |
| Finnish | Triamtereeni |
| Russian | TRIAMTEREN, PTEROFEN, ПТЕРОФЕН, ТРИАМТЕРЕН |
| Japanese | トリアムテレン |
| Polish | Triamteren |
| Spanish | triamtereno (producto), triamtereno (sustancia), triamtereno, Triantereno |
| French | Triamtérène |
| German | Triamteren |
| Italian | Triamterene |
| Portuguese | Triantereno |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Potassium Sparing Diuretics (C0304490) |
|
|---|---|
| Definition (MSH) | A subclass of diuretics that limits the secretion of POTASSIUM into the URINE. |
| Definition (NCI) | Any diuretic agent that produces diuresis without increasing potassium excretion. Potassium sparing diuretics are generally either aldosterone antagonists and thus prevent the aldosterone-mediated promotion of sodium and water retention, or are epithelial sodium channel blockers and prevent the exchange of potassium for sodium in the distal convoluted tubule. These agents cause diuresis without increasing potassium secretion and thus do not cause hypokalemia. |
| Concepts | Pharmacologic Substance (T121) |
| MSH | D062865 |
| SnomedCT | 371337002, 372753003, 47755009 |
| English | Potassium-Sparing Diuretic, K-sparing diuretics, potassium-sparing diuretics (medication), potassium-sparing diuretics, diuretics potassium sparing, potassium-sparing diuretic, potassium sparing diuretic, Diuretics, Potassium Sparing, POTASSIUM-SPARING DIURETICS, POTASSIUM-SPARING AGENTS, Potassium-sparing diuretic product (product), Potassium Sparing Diuretics, Potassium-sparing diuretic (substance), Potassium-sparing diuretic, Potassium sparing diuretic, Potassium-sparing diuretic (product), Potassium-sparring diuretic product, Potassium-sparing diuretic, NOS, Potassium-sparing Diuretics |
| Czech | diuretika šetřící draslík, draslík šetřící diuretika, kalium šetřící diuretika |
| French | Diurétiques épargneurs de potassium, Diurétiques d'épargne de potassium, Diurétiques d'épargne potassique, Diurétiques hyperkaliémiants, Diurétiques épargnant le potassium |
| German | Diuretika, kaliumsparende, Kaliumsparende Diuretika |
| Italian | Diuretici a risparmio di potassio |
| Spanish | Diuréticos Conservadores de Potasio, producto con diurético ahorrador de potasio, producto con diurético ahorrador de potasio (producto), diurético ahorrador de potasio (sustancia), diurético ahorrador de potasio, producto (producto), diurético ahorrador de potasio, producto, diurético ahorrador de potasio, diurético ahorrador de potasio (producto) |
| Polish | Diuretyki oszczędzające potas, Leki moczopędne oszczędzające potas |
| Russian | КАЛИЙСБЕРЕГАЮЩИЕ МОЧЕГОННЫЕ СРЕДСТВА, ДИУРЕТИКИ КАЛИЙСБЕРЕГАЮЩИЕ, KALIISBEREGAIUSHCHIE MOCHEGONNYE SREDSTVA, DIURETIKI KALIISBEREGAIUSHCHIE |
| Croatian | Not Translated[Diuretics, Potassium Sparing] |
| Norwegian | Not Translated[Diuretics, Potassium Sparing] |
| Portuguese | Diurético Poupador de Potássio |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Dyrenium (C0700653) |
|
|---|---|
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D014223 |
| English | Dyrenium, Wellspring Brand of Triamterene |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.
If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.
Please Contact Me as you run across problems with any of these versions on the website.